Last updated: February 16, 2026
Overview of NDC 00904-7334
NDC 00904-7334 corresponds to Ubrogepant (brand name: Ubrelvy), a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine in adults. Approved by the FDA in July 2019, Ubrogepant is positioned as an alternative to triptans, especially for patients with cardiovascular contraindications.
Current Market Penetration and Competitive Position
Market Size:
The migraine market in the U.S. exceeds $4 billion annually, driven by over 37 million diagnosed adults. Ubrogepant entered the market as a non-vasoconstrictive option, targeting patients who cannot tolerate triptans.
Competitors:
- Sumatriptan (Imitrex): $880 million (2022, global sales), a longstanding reliever
- Nurtec ODT (Rimegepant): $650 million (2022, global), shares similar indications
- Ubrogepant: Estimated at $150 million in 2022, with growth potential
Market Penetration Factors:
- Prescribers’ familiarity with triptans favors slow adoption.
- Cost and insurance coverage influence utilization; Ubrogepant's list price is approximately $850 per pack (8 tablets).
- Oral formulation convenience supports outpatient use.
Price Trends and Projections
Current Pricing:
- List Price: Approximately $850 for a package of 8 tablets (80 mg strength).
- Average Wholesale Price (AWP): Estimated at $796.
- Patient Cost (with insurance): Varies, with co-pays around $30-$50.
Pricing Strategy:
Pharmaceutical companies typically set launch prices near competitive equivalents, with potential reductions to incentivize prescriber adoption and insurance coverage.
| Projected Price Trends (Next 3-5 Years): |
Year |
Expected Price Range |
Key Factors |
| 2023 |
$800 - $850 |
Stable, as initial market penetration progresses |
| 2024 |
$750 - $820 |
Slight price reductions to improve insurance coverage and market share |
| 2025 |
$700 - $800 |
Decreased list prices due to increased competition and biosimilar entries |
| 2026 |
$670 - $750 |
Continued reduction, with generic or biosimilar options influence |
Impact of Biosimilars and Generics:
While no biosimilar exists for Ubrogepant, future entries could pressure prices downward by 10-15% annually after patent expiry (~2030).
Market Growth and Revenue Projections
Market Penetration Rates:
- Year 1–2: 10-15% market share among CGRP antagonists
- Year 3–5: 25-35% as awareness and prescriptions increase
Revenue Estimates:
Based on projected market share and pricing, revenues could rise from $150 million in 2022 to approximately $500-700 million by 2026.
Regulatory and Market Factors Affecting Price
- Patent Status: Patents extend to 2030, delaying generic entry.
- Insurance Coverage: Favorable formulary positioning will reduce out-of-pocket costs, boosting utilization.
- Pricing Policies: CMS and insurers impact list price reductions through negotiated rebates.
Key Constraints and Risks
- Competitive pressure from Nurtec ODT, which has similar efficacy profiles but possible better formulary access.
- Pricing elasticity: Price reductions may be necessary to secure insurer coverage.
- Market adoption lag due to physician familiarity with existing therapies.
Key Takeaways
- Ubrogepant's current market price approximates $800 per package, with potential reductions to $700–$750 over the next three years.
- The drug is projected to capture 25-35% of the CGRP market by 2025, with revenues possibly reaching $700 million.
- Competitive dynamics and biosimilar development could accelerate price erosion post-2030.
- Insurance coverage and prescriber familiarity remain key variables influencing market penetration and pricing.
- The patent extension until 2030 provides a six-year window for revenue growth before generic competition emerges.
FAQs
1. How does Ubrogepant compare in price to triptan therapies?
Triptans, like sumatriptan, cost approximately $15–$50 per month, significantly less than Ubrogepant’s ~$850 per package, making Ubrogepant a premium product for specific patient segments.
2. What factors could further influence Ubrogepant’s price?
Market competition, biosimilar development, insurer negotiations, and patent litigation can lead to price adjustments.
3. Is Ubrogepant’s market growth constrained by its pricing?
Initially, yes; high list prices may limit access due to insurer formulary restrictions but could improve with demonstrated cost-effectiveness and increasing prescription volumes.
4. When is a generic version of Ubrogepant expected?
Patent expiration is projected around 2030, after which generic entrants could enter the market, driving prices down.
5. What market strategies could the manufacturer adopt?
Pricing incentives, expanded indications, and demonstration of superior efficacy or safety profiles can boost adoption and justify pricing levels.
References
[1] IQVIA.
[2] FDA, Ubrogepant approval announcement, July 2019.
[3] EvaluatePharma, 2022 Global Migraine Market Data.
[4] Company financial disclosures.
[5] MarketResearch.com, Migraine Treatment Market Outlook.
